Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47


Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions.

Gillet JP, Wang J, Calcagno AM, Green LJ, Varma S, Bunkholt Elstrand M, Trope CG, Ambudkar SV, Davidson B, Gottesman MM.

Mol Pharm. 2011 Dec 5;8(6):2080-8. doi: 10.1021/mp200240a. Epub 2011 Jul 15.


Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer.

Gillet JP, Gottesman MM.

Curr Pharm Biotechnol. 2011 Apr;12(4):686-92. Review.


Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.

Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, Gottesman MM, Varticovski L, Ambudkar SV.

J Natl Cancer Inst. 2010 Nov 3;102(21):1637-52. doi: 10.1093/jnci/djq361. Epub 2010 Oct 8.


Immunohistochemical evidence for the over-expression of Glutathione peroxidase 3 in clear cell type ovarian adenocarcinoma.

Lee HJ, Do JH, Bae S, Yang S, Zhang X, Lee A, Choi YJ, Park DC, Ahn WS.

Med Oncol. 2011 Dec;28 Suppl 1:S522-7. doi: 10.1007/s12032-010-9659-0. Epub 2010 Aug 21.


A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.

Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, Ozbun L, Samimi G, Brady J, Randonovich M, Pise-Masison CA, Barrett JC, Wong WH, Welch WR, Berkowitz RS, Birrer MJ.

Cancer Cell. 2009 Dec 8;16(6):521-32. doi: 10.1016/j.ccr.2009.10.018.


The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer.

Duiker EW, van der Zee AG, de Graeff P, Boersma-van Ek W, Hollema H, de Bock GH, de Jong S, de Vries EG.

Gynecol Oncol. 2010 Mar;116(3):549-55. doi: 10.1016/j.ygyno.2009.09.014. Epub 2009 Dec 3.


Clinical practice. Screening for ovarian cancer.

Clarke-Pearson DL.

N Engl J Med. 2009 Jul 9;361(2):170-7. doi: 10.1056/NEJMcp0901926. Review. No abstract available.


Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database.

Orina JN, Calcagno AM, Wu CP, Varma S, Shih J, Lin M, Eichler G, Weinstein JN, Pommier Y, Ambudkar SV, Gottesman MM, Gillet JP.

Mol Cancer Ther. 2009 Jul;8(7):2057-66. doi: 10.1158/1535-7163.MCT-09-0256. Epub 2009 Jul 7.


Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis.

de Graeff P, Crijns AP, de Jong S, Boezen M, Post WJ, de Vries EG, van der Zee AG, de Bock GH.

Br J Cancer. 2009 Jul 7;101(1):149-59. doi: 10.1038/sj.bjc.6605112. Epub 2009 Jun 9.


Cancer statistics, 2009.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ.

CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.


The peptide-loading complex--antigen translocation and MHC class I loading.

Schölz C, Tampé R.

Biol Chem. 2009 Aug;390(8):783-94. doi: 10.1515/BC.2009.069. Review.


Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.

Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, Levine DA, Boyd J, Alonso MA, Secord AA, Bernardini MQ, Barnett JC, Boren T, Murphy SK, Dressman HK, Marks JR, Lancaster JM.

Clin Cancer Res. 2009 Apr 1;15(7):2448-55. doi: 10.1158/1078-0432.CCR-08-2430. Epub 2009 Mar 24.


Role of BNIP3 and NIX in cell death, autophagy, and mitophagy.

Zhang J, Ney PA.

Cell Death Differ. 2009 Jul;16(7):939-46. doi: 10.1038/cdd.2009.16. Epub 2009 Feb 20. Review.


Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites.

Maelandsmo GM, Flørenes VA, Nguyen MT, Flatmark K, Davidson B.

Tumour Biol. 2009;30(1):15-25. doi: 10.1159/000199447. Epub 2009 Feb 5.


Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma.

Saga Y, Ohwada M, Suzuki M, Konno R, Kigawa J, Ueno S, Mano H.

Oncol Rep. 2008 Dec;20(6):1299-303.


A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer.

Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, Bogomolniy F, Ozbun L, Brady J, Barrett JC, Boyd J, Birrer MJ.

Cancer Res. 2008 Jul 1;68(13):5478-86. doi: 10.1158/0008-5472.CAN-07-6595.


Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells.

Cowden Dahl KD, Symowicz J, Ning Y, Gutierrez E, Fishman DA, Adley BP, Stack MS, Hudson LG.

Cancer Res. 2008 Jun 15;68(12):4606-13. doi: 10.1158/0008-5472.CAN-07-5046.


HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma.

Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, De Geest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AK.

Clin Cancer Res. 2008 Jun 1;14(11):3372-9. doi: 10.1158/1078-0432.CCR-07-4433.

Supplemental Content

Support Center